Payment overview · 2025
General Payments
$1,882.75
92 reported records · 17 companies
Healthcare provider profile · identity verified
Yakov Ryabov, MD
Allopathic & Osteopathic Physicians|Internal Medicine · WHEELING, IL · NPI 1912909615
Verified facts
What the public records show
CMS Open Payments records show Yakov Ryabov, MD received $1,882.75 in general payments during 2025 across 92 reported records.
Corcept Therapeutics accounted for 16.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Eliquis, Farxiga, Jardiance, Kerendia, Linzess, Ozempic, Paxlovid, Rybelsus, Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 118 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Ubrelvy by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 314 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 187 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 471 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 187 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Fiasp as an associated drug or biological on 15 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Fiasp by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 110 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 471 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Paxlovid by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO as an associated drug or biological on 28 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Austedo by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $304.49 | 16.2% | 13 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $241.47 | 12.8% | 14 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $212.96 | 11.3% | 10 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $179.64 | 9.5% | 9 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $167.50 | 8.9% | 9 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $158.77 | 8.4% | 9 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $150.31 | 8.0% | 6 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $117.80 | 6.3% | 5 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $85.94 | 4.6% | 4 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $81.87 | 4.3% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $69.21 | 3.7% | 3 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $23.57 | 1.2% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $21.92 | 1.2% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $18.49 | 1.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $17.37 | 0.9% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $16.62 | 0.9% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.82 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,882.75 | 92 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $304.49 | 13 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $187.01 | 8 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $179.64 | 9 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $167.50 | 9 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $158.77 | 9 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $155.68 | 6 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $152.22 | 10 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $150.31 | 6 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $139.28 | 9 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $106.79 | 4 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $85.94 | 4 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $81.87 | 4 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $46.43 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $42.82 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $39.80 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $23.57 | 1 | 2025 |
Source payment records
|
|||||
| Bulkamid Normalized: bulkamid |
Device | Boston Scientific Corporation | $21.92 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $18.49 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $17.48 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $17.37 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $17.37 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $16.62 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $14.82 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 56 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 471 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 314 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 187 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 118 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 73 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 12 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 110 | exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
56 | 17 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
118 | 24 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
66 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
314 | 48 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
187 | 27 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
471 | 51 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
187 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
49 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Fiasp open payments reported associated product |
CMS Open Payments — General Payments 15 supporting records · 15 recipient NPIs · example record 1188262936 |
Fiasp · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
73 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
110 | 19 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
471 | 51 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
12 | 12 |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 15 recipient NPIs · example record 1247249192 |
Austedo · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1461 | 209 |
| Amlodipine Besylate | Amlodipine Besylate | 1020 | 162 |
| Lisinopril | Lisinopril | 747 | 124 |
| Omeprazole | Omeprazole | 667 | 110 |
| Metformin Hcl | Metformin Hcl | 502 | 84 |
| Levothyroxine Sodium | Levothyroxine Sodium | 473 | 70 |
| Eliquis | Apixaban | 471 | 51 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 470 | 79 |
| Gabapentin | Gabapentin | 455 | 75 |
| Metoprolol Tartrate | Metoprolol Tartrate | 449 | 54 |
| Irbesartan | Irbesartan | 413 | 64 |
| Tamsulosin Hcl | Tamsulosin Hcl | 409 | 65 |
| Metoprolol Succinate | Metoprolol Succinate | 384 | 72 |
| Losartan Potassium | Losartan Potassium | 336 | 62 |
| Chlorthalidone | Chlorthalidone | 322 | 50 |
| Farxiga | Dapagliflozin Propanediol | 314 | 48 |
| Furosemide | Furosemide | 310 | 41 |
| Pantoprazole Sodium | Pantoprazole Sodium | 307 | 55 |
| Trazodone Hcl | Trazodone Hcl | 296 | 44 |
| Risperidone | Risperidone | 278 | 32 |
| Carvedilol | Carvedilol | 269 | 42 |
| Quetiapine Fumarate | Quetiapine Fumarate | 265 | 38 |
| Divalproex Sodium | Divalproex Sodium | 254 | 27 |
| Potassium Chloride | Potassium Chloride | 245 | 32 |
| Xarelto | Rivaroxaban | 245 | 22 |
| Levetiracetam | Levetiracetam | 235 | 21 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 222 | 26 |
| Meloxicam | Meloxicam | 217 | 45 |
| Allopurinol | Allopurinol | 207 | 31 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 207 | 39 |
| Escitalopram Oxalate | Escitalopram Oxalate | 206 | 31 |
| Sertraline Hcl | Sertraline Hcl | 201 | 28 |
| Fluticasone Propionate | Fluticasone Propionate | 194 | 68 |
| Simvastatin | Simvastatin | 191 | 26 |
| Jardiance | Empagliflozin | 187 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 163 | 25 |
| Zolpidem Tartrate | Zolpidem Tartrate | 158 | 29 |
| Mirtazapine | Mirtazapine | 156 | 27 |
| Olanzapine | Olanzapine | 155 | 24 |
| Famotidine | Famotidine | 153 | 29 |
| Diclofenac Sodium | Diclofenac Sodium | 150 | 30 |
| Clonazepam | Clonazepam | 149 | 25 |
| Finasteride | Finasteride | 148 | 25 |
| Latanoprost | Latanoprost | 136 | 15 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 131 | 45 |
| Alprazolam | Alprazolam | 128 | 25 |
| Oxycodone Hcl | Oxycodone Hcl | 127 | 12 |
| Tramadol Hcl | Tramadol Hcl | 126 | 20 |
| Glimepiride | Glimepiride | 122 | 24 |
| Donepezil Hcl | Donepezil Hcl | 121 | 21 |
| Atenolol | Atenolol | 118 | 19 |
| Linzess | Linaclotide | 118 | 24 |
| Benztropine Mesylate | Benztropine Mesylate | 117 | 15 |
| Ibuprofen | Ibuprofen | 112 | 30 |
| Rybelsus | Semaglutide | 110 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 108 | 24 |
| Enalapril Maleate | Enalapril Maleate | 107 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 104 | suppressed |
| Baclofen | Baclofen | 102 | 14 |
| Celecoxib | Celecoxib | 101 | 33 |
| Torsemide | Torsemide | 99 | 19 |
| Midodrine Hcl | Midodrine Hcl | 96 | 19 |
| Haloperidol Decanoate | Haloperidol Decanoate | 93 | 12 |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 91 | suppressed |
| Valsartan | Valsartan | 86 | 15 |
| Hydrochlorothiazide | Hydrochlorothiazide | 85 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 84 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 83 | 20 |
| Memantine Hcl | Memantine Hcl | 83 | 16 |
| Meclizine Hcl | Meclizine Hcl | 82 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 82 | 15 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 81 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 80 | 27 |
| Myrbetriq | Mirabegron | 79 | suppressed |
| Ezetimibe | Ezetimibe | 78 | 12 |
| Haloperidol | Haloperidol | 78 | 15 |
| Metformin Hcl Er | Metformin Hcl | 77 | 13 |
| Nifedipine Er | Nifedipine | 77 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 74 | 12 |
| Ozempic | Semaglutide | 73 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 72 | 21 |
| Spironolactone | Spironolactone | 71 | 16 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 67 | suppressed |
| Januvia | Sitagliptin Phosphate | 67 | suppressed |
| Vascepa | Icosapent Ethyl | 67 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 66 | 15 |
| Synthroid | Levothyroxine Sodium | 66 | suppressed |
| Lidocaine | Lidocaine | 64 | 15 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 63 | 11 |
| Lactulose | Lactulose | 63 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 62 | 12 |
| Venlafaxine Hcl | Venlafaxine Hcl | 60 | suppressed |
| Pregabalin | Pregabalin | 59 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 57 | 12 |
| Paliperidone Er | Paliperidone | 57 | suppressed |
| Prednisone | Prednisone | 57 | 29 |
| Clonidine Hcl | Clonidine Hcl | 56 | suppressed |
| Creon | Lipase/Protease/Amylase | 56 | 17 |
| Benazepril Hcl | Benazepril Hcl | 55 | suppressed |
| Azithromycin | Azithromycin | 53 | 45 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 51 | 19 |
| Oxybutynin Chloride | Oxybutynin Chloride | 51 | suppressed |
| Bumetanide | Bumetanide | 50 | suppressed |
| Lorazepam | Lorazepam | 50 | 12 |
| Clobetasol Propionate | Clobetasol Propionate | 49 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 49 | suppressed |
| Trulicity | Dulaglutide | 49 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 48 | suppressed |
| Colchicine | Colchicine | 48 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 48 | 22 |
| Aripiprazole | Aripiprazole | 46 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 45 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 45 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 43 | suppressed |
| Glipizide | Glipizide | 43 | suppressed |
| Invokana | Canagliflozin | 43 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 43 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 42 | suppressed |
| Ketoconazole | Ketoconazole | 42 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 42 | suppressed |
| Bicalutamide | Bicalutamide | 41 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 41 | suppressed |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 41 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 41 | 11 |
| Prednisolone Acetate | Prednisolone Acetate | 40 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 39 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 39 | 15 |
| Carbamazepine | Carbamazepine | 38 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 38 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 37 | suppressed |
| Clotrimazole | Clotrimazole | 37 | 11 |
| Tradjenta | Linagliptin | 37 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 36 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 36 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 36 | suppressed |
| Clozapine | Clozapine | 35 | suppressed |
| Nystatin | Nystatin | 35 | 13 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 35 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 34 | 28 |
| Doxepin Hcl | Doxepin Hcl | 34 | suppressed |
| Dutasteride | Dutasteride | 34 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 34 | suppressed |
| Primidone | Primidone | 34 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 33 | suppressed |
| Mounjaro | Tirzepatide | 33 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 32 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 32 | suppressed |
| Glipizide Er | Glipizide | 32 | suppressed |
| Austedo | Deutetrabenazine | 31 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 31 | suppressed |
| Gemtesa | Vibegron | 31 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 31 | suppressed |
| Heparin Sodium | Heparin Sodium,porcine | 29 | suppressed |
| Haloperidol Lactate | Haloperidol Lactate | 28 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 28 | 11 |
| Lacosamide | Lacosamide | 28 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 27 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 27 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 27 | 16 |
| Bupropion Hcl | Bupropion Hcl | 27 | suppressed |
| Cephalexin | Cephalexin | 27 | suppressed |
| Lithostat | Acetohydroxamic Acid | 27 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 27 | suppressed |
| Loperamide | Loperamide Hcl | 26 | suppressed |
| Movantik | Naloxegol Oxalate | 26 | suppressed |
| Verapamil Er | Verapamil Hcl | 26 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 25 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 25 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 24 | 17 |
| Entresto | Sacubitril/Valsartan | 24 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 24 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 24 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Methotrexate | Methotrexate Sodium | 23 | suppressed |
| Novolin R | Insulin Regular, Human | 23 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 23 | 18 |
| Acetic Acid | Acetic Acid | 22 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 22 | suppressed |
| Estradiol | Estradiol | 22 | suppressed |
| Insulin Lispro | Insulin Lispro | 22 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Procto-Med Hc | Hydrocortisone | 22 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 22 | suppressed |
| Sucralfate | Sucralfate | 22 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 22 | suppressed |
| Valproic Acid | Valproic Acid | 22 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 21 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 21 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 21 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 21 | suppressed |
| Naproxen | Naproxen | 21 | suppressed |
| Alcohol Swab | Alcohol Antiseptic Pads | 20 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 20 | suppressed |
| Hydrocortisone | Hydrocortisone | 20 | suppressed |
| Digoxin | Digoxin | 19 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 19 | suppressed |
| Kerendia | Finerenone | 19 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 19 | suppressed |
| Timolol Maleate | Timolol Maleate | 19 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 18 | suppressed |
| Phenytek | Phenytoin Sodium Extended | 18 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 17 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 16 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 16 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Methylprednisolone | Methylprednisolone | 16 | 16 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 16 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Veltassa | Patiromer Calcium Sorbitex | 16 | suppressed |
| Bupropion Xl | Bupropion Hcl | 15 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 15 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Acetazolamide | Acetazolamide | 14 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 14 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 14 | suppressed |
| Genvoya | Elviteg/Cob/Emtri/Tenof Alafen | 14 | suppressed |
| Ibu | Ibuprofen | 14 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 14 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 14 | suppressed |
| Oxycontin | Oxycodone Hcl | 14 | suppressed |
| Buprenorphine Hcl | Buprenorphine Hcl | 13 | suppressed |
| Combipatch | Estradiol/Norethindrone Acet | 13 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 13 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 13 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 13 | suppressed |
| Sulfasalazine Dr | Sulfasalazine | 13 | suppressed |
| Brilinta | Ticagrelor | 12 | suppressed |
| Calcipotriene | Calcipotriene | 12 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 12 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 12 | suppressed |
| Dropsafe Pen Needle | Pen Needle, Diabetic, Safety | 12 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 12 | suppressed |
| Isentress Hd | Raltegravir Potassium | 12 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 12 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 12 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Ritonavir | Ritonavir | 12 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Ubrelvy | Ubrogepant | 12 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 12 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 11 | suppressed |
| Cefdinir | Cefdinir | 11 | 11 |
| Ciclopirox | Ciclopirox | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 11 | suppressed |
| Sure Comfort Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Xifaxan | Rifaximin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,882.75 · 92 records | Corcept Therapeutics | AIRSUPRA, AUSTEDO XR, BREZTRI, Bulkamid, CAPLYTA, CREON, ELIQUIS, FARXIGA, IBSRELA, JARDIANCE, Kerendia, Korlym, LEQVIO, LINZESS, NURTEC ODT, Ozempic, PAXLOVID, Rybelsus, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA, VRAYLAR, ZORYVE | 21 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error